Dermira Inc (NASDAQ:DERM) Director Sells $36,000.00 in Stock

Dermira Inc (NASDAQ:DERM) Director Matthew K. Fust sold 3,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $12.00, for a total transaction of $36,000.00. Following the transaction, the director now directly owns 8,051 shares of the company’s stock, valued at $96,612. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of DERM stock traded down $0.17 during trading on Friday, reaching $12.70. 2,006,700 shares of the company’s stock traded hands, compared to its average volume of 1,243,531. The company has a market capitalization of $636.26 million, a P/E ratio of -2.42 and a beta of 1.37. The company has a current ratio of 7.03, a quick ratio of 6.63 and a debt-to-equity ratio of 25.08. The firm’s 50-day moving average is $8.05 and its 200 day moving average is $8.25. Dermira Inc has a 1 year low of $5.25 and a 1 year high of $15.48.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.40) by $0.34. The company had revenue of $11.53 million for the quarter, compared to analysts’ expectations of $11.07 million. Dermira had a negative net margin of 256.08% and a negative return on equity of 583.07%. As a group, sell-side analysts predict that Dermira Inc will post -4.21 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on DERM. ValuEngine downgraded shares of Dermira from a “hold” rating to a “sell” rating in a research report on Thursday. Leerink Swann dropped their price target on shares of Dermira from $23.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Zacks Investment Research upgraded shares of Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 price target on the stock in a research note on Wednesday, October 9th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Dermira in a research note on Friday, October 18th. Finally, Evercore ISI restated a “buy” rating on shares of Dermira in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Dermira presently has an average rating of “Buy” and an average target price of $16.80.

Hedge funds have recently made changes to their positions in the stock. Paradigm Capital Management Inc. NY grew its holdings in shares of Dermira by 0.5% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 251,800 shares of the biopharmaceutical company’s stock valued at $2,408,000 after purchasing an additional 1,200 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Dermira by 2.9% during the 3rd quarter. Rhumbline Advisers now owns 56,909 shares of the biopharmaceutical company’s stock valued at $364,000 after purchasing an additional 1,629 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Dermira by 2.6% during the 3rd quarter. California State Teachers Retirement System now owns 73,649 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 1,857 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of Dermira by 12.3% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 18,552 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 2,031 shares in the last quarter. Finally, Point72 Hong Kong Ltd boosted its stake in shares of Dermira by 124.2% during the 2nd quarter. Point72 Hong Kong Ltd now owns 4,170 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 2,310 shares in the last quarter. Institutional investors own 94.75% of the company’s stock.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Featured Story: What does an outperform rating mean?

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.